

A pancreatic adenocarcinoma mimicking hepatoid carcinoma of uncertain histogenesis: A case report and literature review

ANDREEA ILIESIU^{1,2*}, RADU-VALERIU TOMA^{2,3*}, ANA MARIA CIONGARIU^{1,2},
RADU COSTEA^{2,4}, NARCIS ZARNESCU^{2,4} and LIVIU BÎLTEANU^{3,5}

¹Department of Pathology, University Emergency Hospital of Bucharest, Bucharest 014461;

²Faculty of General Medicine, 'Carol Davila' University of Medicine and Pharmacy, Bucharest 050474;

³Oncological Institute 'Alexandru Trestioreanu', Bucharest 022328; ⁴Second Department of Surgery, University Emergency Hospital of Bucharest, Bucharest 050098; ⁵Department of Preclinical Sciences, Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine, Bucharest 050097, Romania

Received September 23, 2022; Accepted June 19, 2023

DOI: 10.3892/ol.2023.14029

Abstract. In rare cases, metastatic adenocarcinomas of different origin may exhibit the features of hepatoid carcinoma (HC), a rare malignant epithelial tumor, most commonly occurring in the ovaries and stomach, as well as in the pancreas and biliary ducts. A case of a 72-year-old female patient who developed a highly aggressive, poorly differentiated pancreatic ductal adenocarcinoma with peritoneal carcinomatosis, demonstrating hepatoid differentiation upon conventional hematoxylin and eosin staining is reported in the present study. The patient presented with

severe abdominal pain, and the radiological investigations performed revealed ovarian and hepatic tumor masses and peritoneal lesions, which were surgically removed. The gross examination of the peritoneum and omentum revealed multiple solid, firm, grey-white nodules, diffusely infiltrating the adipose tissue. The microscopic examination revealed a malignant epithelial proliferation, composed of polygonal cells with abundant eosinophilic cytoplasm and irregular, pleomorphic nuclei. Certain cells presented with intracytoplasmic mucus inclusions, raising suspicion of a HC with an uncertain histogenesis. Immunohistochemical staining was performed, and the tumor cells were found to be positive for cytokeratin (CK)7, CK18 and mucin 5AC, whereas negative staining for CK20, caudal-type homeobox transcription factor 2, α -fetoprotein, paired box gene 8, GATA-binding protein 3 and Wilms tumor 1 were documented. Thus, the diagnosis of metastatic pancreatic adenocarcinoma was established. The main aim of the present study was to provide further knowledge concerning poorly differentiated metastatic adenocarcinoma resembling HC, emphasizing the histopathological and immunohistochemical features of these malignant lesions and raising awareness of the diagnostic difficulties that may arise, as well as the importance of the use immunohistochemistry in differentiating carcinomas of uncertain histogenesis.

Correspondence to: Professor Liviu Bîlteanu, Department of Preclinical Sciences, Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine, 105 Splaiul Independentei, Bucharest 050097, Romania
E-mail: liviu.bilteanu@fmvb.usamv.ro

*Contributed equally

Abbreviations: AFP, α -fetoprotein; CDH1, cadherin-1; CDH2, cadherin-2; CDKN2A, cyclin-dependent kinase inhibitor 2; CDX2, caudal-type homeobox transcription factor 2; CK, cytokeratin; CRS, cytoreductive surgery; Dkk1, Dickkopf-1; DUPAN-2, duke pancreatic monoclonal antigen type 2; EMT, epithelial-to-mesenchymal transition; FOLFIRINOX, folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin; HC, hepatoid carcinoma; HIPEC, hyperthermic intraperitoneal chemotherapy; mPDA, metastatic pancreatic adenocarcinoma; MUC 5AC, mucin 5AC; nab-paclitaxel, nanoparticle albumin-bound paclitaxel; PAC, pancreatic adenocarcinoma; PAX8, paired box gene 8; PARP, poly ADP-ribose polymerase; PC, pancreatic cancer; PD, pancreaticoduodenectomy; PIVKA II, protein-induced by vitamin K absence or antagonist-II; SNAI1, Snail family transcriptional repressor 1; SPan-1, s-pancreas-1 antigen; Six1, sineoculis homeobox homolog 1; US, ultrasound; VIM, vimentin; VR, vascular resection; WT1, Wilms tumor 1; ZEB1, Zinc finger E-box-binding homeobox 1

Key words: hepatoid, pancreatic, carcinoma, peritoneal, carcinomatosis

Introduction

Hepatoid carcinoma (HC) is a rare extrahepatic epithelial malignancy exhibiting morphological and immunohistochemical features similar to hepatocellular carcinoma (1). HC most frequently occurs in the ovaries, colon or stomach, with only a few cases of pancreatic adenocarcinoma (PAC) of the hepatoid subtype having been reported (2-6). However, several metastatic lesions, including the poorly differentiated adenocarcinoma of the pancreas and stomach, have been reported to exhibit hepatoid morphology (2,7). The clinical course and prognosis of patients developing hepatoid or high-grade adenocarcinoma are always poor, as they rapidly develop metastatic lesions (2). The positive and differential diagnosis

of these entities may be challenging, always requiring ancillary studies and good knowledge of the clinical history of the patient (1,7,8).

The pathological entity with which pancreatic HC is related is PAC, which is one of the leading causes of cancer-related mortality worldwide, mainly presenting at advanced stages, frequently metastatic, with limited conventional treatment efficacy (9,10). As the fourth most lethal form of cancer in the USA, PAC is associated with high mortality and poor survival rates. The incidence of pancreatic carcinoma is increasing worldwide and in western countries (9,11), with its annual incidence having been reported as high as 50,000 patients (12). PAC is estimated to be the eleventh most reported cancer in 2018 (13) or the fourteenth most common cancer, as reported in 2021 (14); however, it is the third or the seventh leading cause of cancer-related mortality, as reported in 2018 (13) and 2021 (14), respectively, mainly affecting older adults. The incidence of PAC is expected to increase further (9), and it is predicted to become the second leading cause of cancer-related mortality in western countries by the year 2030. The median age of diagnosis is 71 years in the USA, with only <1% of diagnoses performed prior to the age of 50. Inherited pancreatic cancer (PC) syndromes and familial PC comprise ≤10% of PAC cases. Despite having been reported as one of the most lethal solid tumors (15), early diagnosis is not frequently achieved, and reliable diagnostic biomarkers are currently lacking.

Identifying modifiable and non-modifiable risk factors for PAC is essential for developing effective preventive strategies and improving patient outcomes. At least 20 possible risk factors for PAC have been identified in prospective cohort studies, with lifestyle and metabolic factors being the most common. These include tobacco smoking, obesity, a sedentary lifestyle, alcohol consumption, an increased fat and red meat intake, a decreased fruit and vegetable intake (16), populations of African descent (17), cadmium, arsenic and lead exposure (18). Other risk factors include a family history (14,19), genetic predispositions (19) or disorders (mutational status of several genes such as BRCA2 or PRSS1, but not only associated with a familial component) (18), long-term diabetes (14,16,17,19–21), chronic pancreatitis (14,16,18,19), certain infectious diseases (involving *Helicobacter pylori*, Hepatitis B virus and human immunodeficiency virus) (18) and intraductal papillary mucinous neoplasms (14). Inherited PC syndromes (hereditary pancreatitis, familial atypical multiple mole melanoma syndrome, and Peutz-Jeghers syndrome) and familial PC comprise 10% of PAC cases (22). Risk prediction models have demonstrated good discrimination and calibration, providing the possibility of early identification and prevention of the disease (16). A recent review (23) proposed a model about how the dysbiosis of microbial and mycobial species may contribute to the development of PAC. The model suggested that bacterial and fungal species in the oral cavity and gut microbiome, including *Porphyromonas gingivalis*, *Fusobacterium nucleatum*, the Proteobacteria, *Helicobacter* spp., and *Malassezia globosa* can cause inflammation and chronic pancreatitis, ultimately leading to PC.

A significant metabolic heterogeneity has been observed in PAC, arising within the ducts of the pancreas (24) and has been linked to the highest rate of cancer-associated venous

thromboembolic disease (25). In total, >50% of PAC patients develop liver metastases (26,27). Tumor initiation leading to PC occurs through acinar to ductal cell metaplasia (28). Previous studies have suggested several causes for pancreatic tumorigenesis. The dysbiosis of micro- and mycobiota contribute to tumorigenesis in PAC (23), while the intratumor microbiome modulating carcinogenesis, has been recently introduced as a new component of the tumor microenvironment (11). Dickkopf-1 (Dkk1), a protein that inhibits the Wnt/ β -catenin pathway and induces apoptosis, exhibits an increased expression in specimens from patients with PAC, and the serum Dkk1-cytoskeleton associated protein 4 (CKAP4)-PI3K/AKT signaling pathway in serum also participates in PC cell proliferation (29). Retinoids play a critical role in maintaining normal pancreatic functions, and the dysregulation of retinoid functions is observed in PAC (30).

Several genetic predispositions and molecular alterations (31) have been found to be associated with this highly lethal entity. The most common mutated oncogenes in PAC and that were among the first to be reported in the literature are KRAS (32) and Bcl-2 (21), while p53 (33–35), deleted in pancreatic cancer 4 (21), cyclin-dependent kinase inhibitor 2 (CDKN2A) (17,35,36), retinoblastoma protein (17,21,33,34,36) are the most frequently deleted tumor suppressor genes. CDKN2A is a gene that encodes proteins involved in regulating the cell cycle, and mutations in this gene are commonly detected in PAC (36). Pathogenic germline alterations are common in individuals with PAC, and ~10% of patients have familial inheritance (17). DNA repair dysfunction involving breast cancer BRCA mutations (19,34,35,37–42), and the polyADP-ribose polymerase (PARP) enzyme (31,34,35) play a crucial role in the pathogenesis of PAC. Next-generation sequencing (26,31) is a technology that allows for the rapid sequencing of DNA or RNA, providing the opportunity for targeted therapy of other mutated genes, including neurotrophic receptor tyrosine kinase (26,33), anaplastic lymphoma kinase (26) and HER2 (31). The TGF- β signaling pathway is frequently altered in PC and acts as an inhibitor and inducer of tumor progression (43). TGF- β signaling was identified as a potent inducer of epithelial-to-mesenchymal transition (EMT), a significant factor in PAC progression and the development of metastases (43). The downstream effects of this duality are critical in the development of metastatic disease, immunologic response, and EMT (44–46). The PI3K pathway (29,47) modifies the tumor microenvironment, and some components of this signaling cascade (such as subunit α of phosphoinositide 3-kinase, phosphatase and tensin homolog, protein kinase B or subunits of PI3K such as p85 α or p110 α) are frequently mutated in PAC. Understanding the genetic and molecular alterations in PAC can lead to targeted therapies and improved treatment outcomes for this highly lethal disease.

Pancreatic HC is a distinct subtype of PAC, hence similar to that of PAC, its pathology is expected to have the same poor prognosis, poor long-term survival (48) and limited availability of therapeutic strategies (49). Late symptoms and treatment resistance contribute to its highly fatal nature, and despite recent improvements, the median overall of patients survival remains as low as ~11 months (43), while the 5-year survival rate ranges from 5 to 17% (25,50–58). Several factors including a lack of screening (54,59,60) and peritoneal metastases

Table I. Immunohistochemistry antibody information.

Antibody type	Staining method	Manufacturer and catalog information	Catalog number	Clone number, clonality	Dilution
AFP	Automatic BOND Leica Biosystems™	MilliporeSigma	A8452-100UL	C3, MMab	1:500
CK 8.18	Automatic BOND Leica Biosystems™	Thermo Fisher Scientific, Inc.	MA5-14088	5D3, MMab	1:50
WT1	Automatic BOND Leica Biosystems™	GeneTex, Inc.	GTX01958	WT49, MMab	1:100
CEA	Automatic VENTANA Roche™	Abcam	ab193372	CEA31, MMab	1:100
PAX8	Automatic VENTANA Roche™	MilliporeSigma	363M-18	MRQ-50, MMab	Ready-to-use
MUC 5AC	Manual BSB	MilliporeSigma	MAB2011	CLH2, MMab	1:50
GLYPICAN	Manual BSB	MilliporeSigma	261M-9	1G12, MMab	1:200

AFP, α -fetoprotein; BSB, biotin-streptavidin-peroxidase; CK, cytokeratin; PAX8, paired box gene 8; MMab, mouse monoclonal antibody; MUC 5AC, mucin 5AC; 3WT1, Wilms tumour 1.

also affect prognosis (58). With a relatively better prognosis, pancreatic acinar cell carcinoma has a 5-year survival rate of ~15% (28). Prognostic factors include tumor size (58), differentiation (58,61), margins (58,62), lymph node invasion (58,62) and high-grade tumor budding (63). Exercise during treatment is crucial for the optimization of the quality of life; however, well-designed trials are required (64). The low socio-economic status of patients in Europe and North America is associated with a reduced access to surgery or an increased likelihood of refusing surgery, which is influenced by a low income, poor levels of education, insurance coverage and rural areas (65).

Surgical resection is the only curative option limited to a limited number of candidates (56). Multidisciplinary therapy (12,66,67) is required for locally advanced disease, and suboptimal chemotherapy response is a major concern. Recent chemotherapy, radiation, and immunotherapy advancements have improved short-term survival, and new therapeutic regimens are being developed (68). Artificial intelligence can potentially improve diagnosis and treatment, and novel approaches are undergoing preclinical and early clinical evaluation (54).

Case report

A 72-year-old female patient presented to the Emergency Clinical Unit and further hospitalized in the Second Department of Surgery, University Emergency Hospital of Bucharest (Bucharest, Romania), where laboratory tests and radiology investigations, including ultrasonography and CT scan, indicated the presence of hepatic and ovarian tumor masses and aroused suspicion for peritoneal carcinomatosis. Therefore, the affected peritoneum and omentum were surgically excised and submitted to the Department of Pathology. The samples were fixed with 10% neutrally buffered formalin at 4–8°C overnight (20 h) and then processed by conventional histopathological methods using paraffin embedding, sectioning (3–5 mm) and hematoxylin-eosin staining at

room temperature (5–10 min for hematoxylin and 1–5 min for eosin). The slides were observed using light microscopy. Afterwards, the sections were deparaffinized in toluene and alcohol, washed in PBS (phosphate saline buffer), incubated with normal serum, and then incubated with primary antibody overnight. Subsequently, washing in carbonate buffer and developing in 3,3'-diaminobenzidine hydrochloride/hydrogen peroxide (MilliporeSigma) and nuclear counterstain with Meyer's hematoxylin (MilliporeSigma) was performed according to the provided manufacturer's protocol, at room temperature for 1–5 min. Normal human serum (MilliporeSigma) at a concentration of 10% was used as the blocking reagent, performed at room temperature. Overall, the following immunohistochemical markers and corresponding antibodies were used: Cytokeratin (CK)7, CK20 and CK8/18, α -fetoprotein (AFP), paired box gene 8 (PAX8), caudal-type homeobox transcription factor 2 (CDX2), GATA-binding protein 3, mucin 5AC (MUC 5AC) and Wilms tumor 1 (WT1) (Table I). Staining was performed either manually using a biotin-streptavidin-peroxidase complex technique or automatically with the Leica Biosystems Bond™ or Roche Ventana™ immunohistochemistry staining systems. The staining method is specified along with the automatic staining system in the second column of Table I. The antibody clone information as listed by the manufacturers is also stated.

Furthermore, inserting the search query '[pancreas(Title) OR pancreatic(Title)] AND hepatoid carcinoma[Title]' into the PubMed database, all English language cases published until February, 2023 were reviewed, by also including all reported patients of any age and sex developing metastatic pancreatic carcinoma confirmed by histopathologic examination and immunohistochemical analysis, further investigating the cases with hepatoid morphology. All of the reported cases which referred to metastatic HC of ovarian, gastric and colonic origin were excluded.

The case of a 72-year-old female patient with a medical history of hypertension under treatment and grade II obesity



Figure 1. Computed tomography abdominal scan showing hepatic tumor, ascites and peritoneal nodes.

was investigated in the present study, who presented to the Emergency Clinical Unit of the University Emergency Hospital of Bucharest with complaints of severe abdominal pain and abdominal distension. The patient was further hospitalized in the Second Department of Surgery. Blood biochemistry later revealed that the patient had chronic high glucose levels with HbA1c levels at 7.1%, which is a diagnostic criterion of type 2 diabetes (69). A computed tomography (CT) scan (Fig. 1) was performed, revealing hepatic and ovarian tumor masses and multiple nodular lesions of the peritoneum and greater omentum, raising concern about an extensive abdominal neoplasm. The hepatic lesion involved segments II and III presented with multiple calcifications. On the CT scan, the clinical image of the pancreas appeared to be within normal limits.

Ascitic fluid was observed, and a sample was submitted for cytological analysis upon which malignant epithelial cells and acute inflammatory infiltrate were identified. The serum tumoral markers analysis revealed the following values: CA125, 280.9 U/ml; CEA, 18.8 ng/ml; CA19-9, >1,972 U/ml; and AFP, 3.11 ng/ml. The peritoneum and greater omentum were surgically excised during open surgery and submitted to the Department of Pathology. The gross examination of the specimens revealed multiple infiltrative, solid, firm, grey-white nodules involving the entire adipose tissue.

The histological examination of the fragments revealed a malignant epithelial proliferation exhibiting a diffuse sheet-like growth pattern, occasionally forming cords and pseudoglandular structures (Fig. 2). The neoplastic cells demonstrated a particularly polygonal morphology, with marked nuclear pleomorphism, loss of nuclear polarity, atypical mitoses and prominent nucleoli, and abundant eosinophilic cytoplasm containing mucin granules (Fig. 2). The malignant tumor exhibited a deeply infiltrative growth pattern and marked desmoplastic stromal proliferation. The angiolymphatic neoplastic invasion was also documented. As the histopathological aspect of the lesion and clinical data




Figure 2. Highly pleomorphic epithelial proliferation exhibiting a diffuse sheet-like growth pattern and marked desmoplasia (hematoxylin and eosin staining, x10 magnification). Cell-level features are shown in the inserted zoomed-in image (200%): Loss of nuclear polarity and polygonal morphology (yellow arrow), marked nuclear pleomorphism and prominent nucleoli (black arrow), atypical mitoses (red arrow), abundant eosinophilic cytoplasm containing mucin granules (green star).

were highly suggestive of HC, several immunohistochemical examinations were performed. Firstly, AFP, PAX8 and WT1 expression analysis revealed negative staining of the neoplastic cells, excluding an ovarian HC origin (Fig. 3). The absence of CDX2 expression within the tumor cells excluded a presumptive colonic origin of the metastatic lesion (Fig. 4). The possible pancreatic-biliary origin of the malignant lesion was later studied by using low molecular weight MUC 5AC (Fig. 5A) and CKs (Fig. 5B and C). The tumor cells demonstrated CK7-positive (Fig. 5B) and CK20-negative (Fig. 5D) staining. The intense expression of MUC 5AC (Fig. 5A) and CK18 (Fig. 5C) within the neoplastic cells eventually established the diagnosis of metastatic PAC.

Due to advanced metastatic neoplastic condition, the patient passed away shortly after the surgery, and no specific oncological treatment had been established due to the fulminant lethal course of her disease. The histopathological diagnosis was finalized at approximately the same time. No non-surgical treatment was initiated due to the fulminant lethal course of the disease.

Discussion

HC is a rare epithelial neoplasm with an uncertain histogenesis, which most frequently involves the ovaries or the digestive tract, particularly the colon and stomach (8). Although very few cases have been reported, the described tumor can also develop in the pancreatic head (2,8).

Rare tumors are classified *a priori*, within the predictive, preventive and personalized treatment spectrum; however, since they are only detected with a reduced frequency in the total population, their susceptibility to adverse disease progression and the response to targeted therapeutic strategies remains to be investigated further with the use of genomics. Immunohistochemical analysis provide results that, considered that they provide information concerning pathological




Figure 3. Immunohistochemistry images (x10 magnification): (A) Absence of AFP expression in the tumor cells ruling out hepatoid differentiation of the malignant lesion; (B) negative paired box gene 8 staining within tumor cells ruling out ovarian origin of the malignant lesion of the greater omentum.




Figure 4. Negative caudal-type homeobox transcription factor 2 staining in the neoplastic epithelial cells excluding the presumptive 'intestinal' differentiation of the epithelial neoplasm (immunohistochemistry images, x10 magnification).




Figure 5. Immunohistochemistry images (x10 magnification): (A) Diffuse intense expression of mucin 5AC within the malignant epithelial proliferation. (B) Intense cytoplasmatic and membranous expression of cytokeratin 7 within neoplastic cells. (C) Diffuse intense cytokeratin 18 positivity within tumor cells, suggesting pancreatobiliary origin of the neoplastic proliferation. (D) Absence of cytokeratin 20 expression within tumor cells.

mechanisms, can be incorporated in genetic tests with a predictive role for tumor development and with a possible supporting

role in decision-making, in relation to therapeutic strategies targeted at specific patient groups.

Although not well defined, the pathogenesis of pancreatic HC can be summarized into three hypotheses (70) (Fig. 6). The first one is the ectopic tissue hypothesis, according to which HC may have origins in ectopic hepatic tissue in the pancreas (71,72). Secondly, the pancreas to hepatic transdifferentiation hypothesis explores the possibility of the pancreatic cells being able to transdifferentiate into hepatocytes. Lastly, the pancreatic multipotent stem cell hypothesis states that the liver and pancreas have the exact embryological origin in the foregut endoderm and share activating genes that control differentiation during carcinogenesis (70-72). Considering the morphological and immunohistochemical aspect, pancreatic HC can be further classified as a pure or mixed type, and the latter can be associated with other component types, including ductal adenocarcinoma and acinar cell carcinoma (73). Using the PubMed search query, '[Pancreatic(Title) OR pancreas(Title)] AND adenocarcinoma[Title]', 9,800 studies related to PAC were discovered (on February 19, 2023) in the literature, of which 39 were pure-type and 16 were mixed-type pancreatic HCs (6,70). Regardless of the affected organ, this malignancy is always associated with aggressive clinical behavior, as the patients either decease due to the rapid disease progression or develop multiple recurrences and distant metastases (2,74). PACs are rapidly progressive epithelial neoplasms which may exhibit hepatoid features upon microscopic examination (75,76). This diagnosis is associated with a poor prognosis, due to early micrometastatic spread with a limited 5-year survival of <3% (77).

The poorly-differentiated variants of PAC can present as deeply infiltrating lesions, composed of large, polygonal neoplastic cells with abundant eosinophilic cytoplasm and pleomorphic nuclei with open chromatin, prominent nucleoli, mimicking hepatoid tumors and even hepatocellular carcinoma (75,78,79). Some patients developing this highly lethal malignancy are frequently diagnosed with a metastatic lesion at the time of first diagnosis (80). Although PAC and HC are rapidly progressive tumors associated with metastases, including peritoneal carcinomatosis, patients developing hepatoid lesions may exhibit elevated serum levels of AFP (1,2,6,79,81). In the case described in the present study, the initial presentation implied the identification of peritoneal carcinomatosis, with no increase in serum AFP levels. However, the histopathological examination of the specimens revealed malignant epithelial proliferation, mainly composed of large, polygonal cohesive neoplastic cells with abundant eosinophilic cytoplasm, displaying a sheet-like growth pattern, with occasional forming of cellular cords and pseudoglandular structures. The most peculiar aspect identified within the tumor was intracytoplasmic basophilic granules, raising concern about HC with an ovarian origin, particularly considering that an ovarian mass was detected by the CT scan. The neoplastic cells within hepatoid ovarian carcinoma usually exhibit AFP expression; however, they are also positive for PAX8 and WT1, with their origin being the surface ovarian epithelium (2,8,82). In the case described herein, no expression of PAX8 or AFP was detected in the tumor cells, simultaneously excluding the possibility for the ovarian origin of the lesion and an hepatoid phenotype. However, as mentioned earlier, the microscopic




Figure 6. Hypotheses of the pathogenesis of hepatoid carcinoma: (A) Hypothesis of ectopic liver tissue; (B) hypothesis of transdifferentiation of pancreatic cells into liver cells; (C) hypothesis of common genetic activation of pancreatic and liver cells due to the common origin of the two types of cells in the embryonic foregut.

examination of the fragments obtained from the peritoneum and omentum revealed a deeply infiltrative tumor proliferation, predominantly composed of atypical cells, exhibiting mucus secretion and pseudoglandular structures, distorted by a thick fibrous and inflammatory stroma.

Hepatoid tumors are often negative for CK7 and positive for the pan-cytokeratin markers, AE1/AE3 (92%), CK19 (94-100%), glypican-3 (78%), arginase-1 (75%), CK20 (25-47%) and CK18 (70,81,83). The possibility of the tumor being classified as a poorly differentiated adenocarcinoma with a gastric or pancreatic origin was also considered; thus, further concomitant analyses were performed. Firstly, CK7, CK20 and MUC 5AC staining was performed, in order to investigate the hypothesis of the pancreato-biliary or gastric origin of the neoplasm. Furthermore, CK18 was considered as a valuable marker for the confirmation of the pancreatic origin of the peritoneal metastases, as several studies previously suggested that it can be detected in metastatic PAC and cholangiocarcinoma (84,85). It is considered that positive CK18 staining of neoplastic cells has a more optimal diagnostic value when CK20 is not expressed within the tumor (85,86). MUC 5AC expression in the neoplastic cells has also been analyzed, since there is significant evidence of the critical role of mucin expression in colorectal and pancreatic carcinogenesis (86,87). Eventually, positive CK7, CK18 and MUC 5AC staining, correlated with the lack of CK20 expression within

the patient examined or the present case report, confirmed the diagnosis of metastatic poorly differentiated PAC.

In simple, pseudostratified, ductal epithelium, mesothelium, and urothelium, CK7 has a similar, although more restricted expression than CK8 and CK18. It is a cytoplasmic or membranous marker that is detected in both normal epithelia and generally expressed in a broad spectrum of malignancies, albeit with considerable variation. CK18 is predominantly expressed in simple epithelial cells, eccrine glands (88), small dimension vessels (89) and trophoblasts (90). MUC 5AC is expressed in various parts of the digestive system, particularly in the gastric antrum, superior airways and metaplastic endometrium (91).

Despite the widespread distribution of CK7 expression, it is a valuable component of a panel for diagnosing the primary location of metastatic cancer. Its expression is usually concurrently analyzed with CK20 in tumors of various types and localizations. Similarly, CK7 and CK18 are expressed in various tumors, as presented in Table II.

Several other immunochemical biomarkers are mentioned in the literature; however, relevant techniques for their identification were unfortunately unavailable for the present study. The lack of the evaluation of the aforementioned markers would constitute a limitation of this diagnostic and treatment strategy of the present case report. For instance, a recent study proposed that cadherin-1 (CDH1), cadherin-2 (CDH2), Vimentin (VIM), Zinc finger E-box-binding homeobox 1 (ZEB1), and Snail family transcriptional repressor 1 (SNAIL) could be potential diagnostic, prognostic, and therapeutic targets for PAC (92).

The most frequently mentioned, CDH1, is a protein associated with cell adhesion and known to be involved in tumor progression, invasion and metastasis (93,94). Moreover, the complete or partial loss of CDH1 expression plays a predictive role in the development of the disease, as it is an independent predictor of poor outcomes among patients with PAC undergoing pancreaticoduodenectomy (PD) (95), being primarily related to a worse median survival than in patients with a uniformly intact CDH1 expression, but also to frequent lymph node metastasis and an advanced clinical stage (96). More precisely, the CDH1 gene polymorphism is associated with an increased risk of PC in the Chinese population; however, larger samples are required to confirm these findings (97). In particular, a higher histological grade PAC is related to CDH1 methylation promoter encountered in long-term diabetes patients with pancreatic cancer (98). A similar effect in tumorigenic transformation through EMT is exerted by CDH2 (99,100).

However, CDH1 is not PAC-specific, being also a biomarker involved in the diagnosis of hereditary diffuse gastric cancer, and may not always initiate the development of PAC when both pathologies are present in the same patient (101). In the absence of conclusive imaging results regarding the damage to abdominal organs, CDH1 positivity would support the hypothesis concerning the gastric origin of the tumor.

Along with the investigation of ZEB1, VIM, or SNAIL, the detection of CDH1 could have contributed to finalizing the diagnosis and disease development prediction. ZEB1 is an EMT-related transcription factor. ZEB1 levels have been negatively associated with PC, through its involvement with

inositol-3-phosphate synthase 1 into a pathway that enhances cancer cell migration and invasion (102). Additionally, ZEB1, in combination with CDH1, has already been confirmed as a negative prognostic biomarker by previous studies (99,103), ZEB1 acting as a repressor of both CDH1 (104) which is a controller and of epithelial cell adhesion molecule, which is a regulator of the migrating cells adhesiveness (105). Metastatic tumors with a larger diameter exhibit an increased expression of CDH1 and a decreased expression of ZEB1 and SNAIL, as compared with smaller metastases (104). VIM has been suggested as a predictive biomarker for the PC evolution (106) in parallel with CDH1 (107). Additionally, CDH1, VIM and ZEB1 have been suggested as diagnostic and predictive biomarkers for intraductal papillary mucinous neoplasm (108).

Following surgery survival or in the absence of surgical indication, the evaluation of those biomarkers could have allowed the administration of targeted treatment since they have been proposed as possible therapeutic targets. Blocking CDH1 inhibits PAC progression by facilitating its expression through the enforced expression of miRNA-101 (93,96). The metastasis-associated with colon cancer protein 1/SNAIL complex in EMT, a therapeutic target in PC, has been reported to downregulate CDH1. CDH1 is downregulated when sine oculis homeobox homolog 1 (Six1) is inhibited, and tumors with impaired Six1 expression exhibit loss of the CD24⁺/CD44⁺ phenotype. Therefore, Six1 may be a potential therapeutic target for PC (109). The downregulation of VIM inhibits cancer cell migration and may affect the response to chemotherapy (106). Along with ZEB1, SNAIL, SNAIL2 and CDH2, VIM is involved in the NF- κ B signaling pathway, inducing EMT and promoting lymphovascular and neural invasion; thus, over the past decade, these markers have been proposed as potential therapeutic targets for inhibiting PC progression (110). However, the positive results of such targeted treatments are not supported by extensive studies, being otherwise currently unavailable in the literature.

Early PC detection is hindered by the lack of a strategy to identify high-risk individuals (14). It has been suggested that a more targeted screening approach based on modifiable and non-modifiable risk factors might be more efficient, particularly for individuals with inherited and familial PC syndromes (22). Early detection of PAC is crucial for improving therapeutic outcome, and current screening methods are primarily imaging-based. The interest in detecting PAC and precursor lesions at an early stage has led to the developing PC screening programs (56).

The accurate staging of PAC is essential, due to the metastatic nature and course of treatment of the disease (111). Therefore, imaging techniques are essential in differentiating metastatic disease from other entities (56). Novel imaging techniques (56), including dual-energy CT, diffusion-weighted MRI and positron emission tomography/MRI, are being developed to improve the accuracy of diagnosing PC. Multimodality imaging (pancreatic protocol CT and magnetic resonance cholangiopancreatography) and interventional endoscopy [endoscopic retrograde cholangiopancreatography and endoscopic ultrasound (US)] are currently used for diagnosis and staging (50); however, monitoring treatment response remains challenging. Complete surgical resection should be mandatory whenever possible, followed by adjuvant chemotherapy and

Table II. Common immunochemical features (CK7, CK18, CK20 and MUC 5AC) of tumors with various localizations, according to the literature.

Tumor	CK7	CK18	CK20	MUC 5AC	(Refs.)
Gastrointestinal tumors					
Esophageal adenocarcinoma	+	NA	-	NA	(159)
Gastric adenocarcinoma	+	+	+	NA	(160)
Diffuse carcinoma	NA	NA	NA	+	(161)
Lymph nodes of gastric carcinoma	NA	+	NA	NA	(161)
Small intestinal adenocarcinoma (67%)	+		+	NA	(162)
Colon carcinoma (in lymph nodes)	NA	+	NA	NA	(163)
Pancreatic adenocarcinoma					(8,70)
Poor prognosis	+	NA	+	NA	
Good prognosis	+	NA	-		
Hepatocellular adenocarcinoma		+		NA	(164)
Hepatoid carcinoma mimicking hepatocellular adenocarcinoma		+		NA	(165)
Carcinoma of the bile duct					(166)
Extrahepatic	+	NA	+	NA	
Intrahepatic	+		-	NA	
Gynecological tumors					
Endometrial adenocarcinoma	+	NA	-	NA	(167)
Ovarian mucinous tumors	+	NA	+	+	(80,81,168)
Cervical and uterine cancer	+	NA	+	NA	(169,170)
Breast cancer					(171,172)
Invasive disease	+	+	-	NA	
Other					
Head and neck cancer					(70,173,174)
Sinonasal	+	NA	+	NA	
Lung adenocarcinoma	+	NA	-	NA	(175)
Urinary tract cancer	+	+	+	NA	(176)

Existing studies prove that the marker is positive (+) or negative (-) in the listed localisations. NA, non-available information; CK, cytokeratin; MUC 5AC, mucin 5AC.

depending on the case of metastatic disease, hyperthermic intraperitoneal chemotherapy (HIPEC) can be considered (76,112,113). A review of four studies evaluating the use of HIPEC in PAC after surgical resection demonstrated overall survival rates ranging from 2 to 62 months with an 8.5% hospital mortality rate (114). However, due to a small sample size and low-quality evidence, no valid conclusions could be drawn. In a study in which three therapeutic strategies were used [cytoreductive surgery (CRS) with HIPEC, prophylactic HIPEC, and neoadjuvant intraperitoneal chemotherapy], it was concluded that the use CRS and HIPEC in peritoneal carcinomatosis of pancreatic origin was considered not useful and unsafe (115).

Several studies have demonstrated the benefits of surgery even for isolated recurrences of PAC (116). However, <20% of patients are candidates for curative resection (117). Attempted resection rates, margin negative resection rates and pathological response are the outcomes measured for surgical resection (118). Palliative local treatments are preferred alternatives to surgery (26). However, although

only 10-20% of patients are candidates for curative resection, vascular bypass graft techniques and neoadjuvant treatment regimens have increased the curative resection rate (56,117). Attempted resection rates, margin negative resection rates, and pathologic response are the outcomes measured for surgical resection (118). Radical resections increase margin negativity and life expectancy (48).

Conversion surgery for initially unresectable tumors is associated with improved survival, and no significant difference in survival was observed between patients with locally advanced disease and those with distant metastases after conversion surgery (119). A systematic review of published evidence on locally advanced PC treatment strategies with curative intent (120) reported that the median resection rate was 25%, with 33.5% of patients proceeding to surgery after completion of the neoadjuvant pathway (121). Median progression-free and overall survival for resected patients may reach 12.9 (122) and 30 (123) months, respectively. The extent of surgery applied is controversial; lymphadenectomy, nerve plexus, retroperitoneal tissue, vascular and multi-visceral resections,

total pancreatectomy, and liver metastases are discussed in a review of the basic underlying concepts and the roles of radical surgery (48). In a systematic review comparing PD with and without vascular resection (VR) in pancreatic head adenocarcinoma, it was reported that the PD+VR group demonstrated lower 1-, 3- and 5-year overall survival rates. The PD+VR group presented with larger tumors, positive lymph nodes, and higher R1 resection. The reported 30-day mortality was higher in the PD+VR group, and no differences were observed between groups in post-operative complications (124). Hepatic resection for patients with PC with hepatic metastases is a safe procedure and provides an additional survival benefit in the medium term (<3 years); however, further randomized, controlled trials are urgently required (27).

Laparoscopic pancreatic surgery is a safe and feasible option for carefully selected patients and has been suggested to improve surgical outcomes; however, further confirmation is necessary through randomized controlled studies (125). Irreversible electroporation is being explored as a potential treatment for locally advanced PC, and while some preliminary evidence is promising, IRE should only be used after conventional treatments and within the research context (126). Minimally invasive distal pancreatectomy is safer than open distal pancreatectomy for patients with PAC, with lower positive surgical margin rates, less blood loss, a shorter hospital stay, and lower morbidity and mortality (127). High-intensity focused US (HIFUS) is an emerging therapeutic modality for PC, inducing mechanical effects for targeted drug delivery and pain management in palliative care and for downstaging borderline resectable tumors (53). With the advancement of emerging therapeutic modalities including sonodynamic therapy and immunomodulation, HIFUS may be a promising option for improving outcomes.

However, due to its aggressive nature and the possibility of early hepatic metastasis, some authors present the utility of neoadjuvant chemotherapy, surgery and adjuvant chemotherapy with results that are yet unclear and remain to be elucidated further (41,128-130). The standard treatment care for PC in clinical practice is the application of combination chemotherapy (131,132). Conventional chemotherapy offers a low 5-year survival rate due to its limited efficacy and suboptimal response (133). Patients with DNA repair dysfunction, including BRCA mutations, benefit from platinum chemotherapy and PARP inhibitors (31). Limited success has been reported concerning the use of therapies, including gemcitabine (134). The use of folinic acid, 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) has been reported to exhibit comparably increased efficiency, although presenting with an increased toxicity (135). FOLFIRINOX and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine have demonstrated benefit (134), while a modest improvement in survival has been observed with gemcitabine-erlotinib and FOLFIRINOX (135). The median overall survival for patients with metastatic pancreatic adenocarcinoma (mPDA) treated with first-line regimens remains as low as 1 year, indicating a significant need for effective later-line options, nab-paclitaxel being one such example (31).

The global analyses of gene expression in PC led to the discovery of several potential new PC markers (52). Database searches in a previously published study identified 76 independent prognostic and predictive molecular markers

implicated in pancreatic tumor growth, apoptosis, angiogenesis, invasion and resistance to chemotherapy. Researchers are investigating these biomarkers, in order to capture phenotypic variability and identify PC earlier, including small extracellular vesicles, microbial signatures, proteins, metabolites, genetic and epigenetic markers (52). CA19-9 is the most commonly used biomarker, although with limited specificity for PC and sensitivity in the early PC stages (136); thus, new biomarkers clinically validated by prospective studies are needed for early detection and subsequent death rate reduction (137). Of these, 11 markers (Ki-67, p27, p53, TGF- β 1, Bcl-2, survivin, VEGF, cyclo-oxygenase 2, CD34, S100 calcium-binding protein A4 and human equilibrative nucleoside transporter 1) provided independent prognostic or predictive information in two or more separate studies. In addition, thrombospondin-2, insulin-linked binding protein 2, lysophosphatidic acid, autotaxin, inflammatory factors, coagulation factors (61) and Dkk1 (29) are possible simple protein biomarker candidates. Mesothelin was identified by serial analysis of gene expression as overexpressed in 80-90% of PC cells. However, limited expression of mesothelin has been observed in normal tissues, being thus a valuable diagnostic aid and a therapeutic target (137). Soluble mesothelin-related proteins may potentially be part of a panel of markers for pancreatic carcinoma, along with previously used markers, including CA19-9, CEA, and tissue inhibitor of metalloproteinases-1 (138,139).

Several serum biomarkers, including protein-induced by vitamin K absence or antagonist-II (PIVKA II), Duke pancreatic monoclonal antigen type 2 (DUPAN-2), and s-pancreas-1 antigen (Span-1) in conjunction with 'classical' non-specific tumor markers (for example, CA19-9 or CEA) have been studied as risk factors for the evolution of patients with PAC. PIVKA II was identified as having higher serological levels in PC, thus being considered as a possible biomarker for this pathology (140). A subsequent study by the same group of authors revealed that PIVKA II can also be used as a predictive biomarker of postoperative evolution in small stages (141). In addition, it has been demonstrated that PIVKA II can function as an excellent marker in rare cases of hepatoid pancreatic adenocarcinoma demonstrated, while its increased levels have also been associated with a positive diagnosis of hepatocellular carcinoma (142).

DUPAN-2, CEA and CA19-9 positivity, in conjunction with certain levels for the first two and tumor sizes >30 mm, are indications of resectable or non-resectable tumors (143). In addition, DUPAN-2 has been used to monitor the response to chemotherapy (144). DUPAN-2 can potentially predict the prolonged survival of patients with PC during initial systemic therapy and may be useful in determining the optimal timing for conversion surgery in initial systemic therapy (145). Thus, together with CA19-9, DUPAN may aid in patient stratification and personalized treatment decisions (146).

Span-1 is a biomarker used in PC that plays a predictive role in the evolution of the disease. Preoperative serum Span-1 >37-41 U/ml (147,148) levels are significantly associated with a higher early recurrence risk following the curative resection of PC. Therefore, Span-1 may be useful for determining the best treatment option for patients with resectable PC.

Span-1 is as useful as CA19-9 for monitoring the success of gemcitabine chemotherapy (149). Moreover, SPan-1 and CA19-9 have been identified as independent risk factors for early recurrence in patients who underwent surgical resection for PC: Patients with both biomarkers presented with a higher rate of lymph node metastasis than patients with one increased biomarker or none altered (150), whereas higher levels of CA19-9, SPAN-1 together with low mitochondrial OGG1 expression are indicators of perineural invasion (151).

Recently, the former two biomarkers have been included in various scores, e.g., a preoperative tumor marker index whose high values have been associated with larger tumors, lymph node metastases, and worse prognostic outcomes in terms of both relapse-free survival and overall survival (152). Another example of a predictive score is the early recurrence prediction score, which identifies patients with poor prognoses and avoids unnecessary surgery (153). However, elevated post-operative CA19-9 instead of either Span-1 or DUPAN-2 (154), was identified as the strongest predictive marker of poor survival in the pre- and post-operative period, being thus a biomarker of choice for post-operative evolution. However, complementing the preoperative serum levels of CEA, CA19-9 with values of Span-1 and DUPAN-II would have been necessary to further support surgical indication.

Liquid biopsies and next-generation sequencing of circulating tumor cells enable novel PC diagnostics and therapeutics, allowing prognosis (57,155) by detecting circulating nucleic acid-based biomarkers (42,156), including non-coding miRNAs (157). Genetic testing for germline BRCA1 and 2 pathogenic variants is crucial for all newly diagnosed patients with mPDA, considering the solid hereditary component of the disease (31,37,39). Additionally, identifying active oncogenic pathways and gene-gene interactions has been suggested to reveal oncogene addiction and synthetic lethality, which can provide a basis for developing personalized treatments (155). Additionally, identifying active oncogenic pathways and gene-gene interactions can reveal oncogene addiction and synthetic lethality, which can provide a basis for developing personalized treatments (155). However, challenges including sensitivity and analytical limitations still exist, which require further research (156).

Identifying biomarkers that accurately predict disease recurrence or response to chemotherapy would substantially aid individual risk assessment and treatment selection, possibly also leading to novel therapies by becoming targets for molecular intervention in specific subsets of patients.

In conclusion, the positive and differential diagnosis of metastatic adenocarcinoma with hepatoid morphology revealed associations between standard histopathological examination and the expression of immunohistochemical markers. Furthermore, due to the highly aggressive clinical outcomes of this malignancy, establishing the origin of peritoneal metastases is crucial for the evaluation of the prognosis and response of the tumor to surgical and oncological treatment. The establishment of a neoadjuvant therapy for pancreatic neoplasms in general (118,158), and for tumors as uncharacteristic and as aggressive as the hepatoid pancreatic adenocarcinoma presented in the present study is rare; however, immunohistochemical studies contribute to opening up new perspectives for early diagnosis and improvement of

neoadjuvant treatments or curative strategies. Case report studies should not be considered solely as descriptions of rarely occurring tumors but an opportunity to gain further immunological insight. As has been demonstrated in the present study, pancreatic adenocarcinoma is very aggressive, regardless of its histopathological typology, mainly associated with other aggravating factors including multi-organ dissemination and risk factors (comorbidities, old age).

Acknowledgement

Not applicable.

Funding

Publication of this paper was supported by the University of Medicine and Pharmacy ‘Carol Davila’ through the institutional program ‘Publish, not Perish’.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

AI, RVT and LB participated in the conceptualization of the study. LB performed the validation of the manuscript plan according to available data. RC and NZ performed the surgery, while AI and AMC conducted the medical investigation of the pathology slides. AI, AMC, RC and NZ gathered all necessary resources. AI and RVT conducted all data curation. AI, LB and RVT prepared the original draft of the manuscript. AI, RVT, NZ, RC, and AMC reviewed and edited the manuscript. LB and RVT realized the Figures. AI, LB and RVT supervised the present study. AI and LB confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

The patient's informed consent was obtained to use the biological material for ancillary studies, including also the consent for the publication of personal information as presented in imaging body scans.

Competing interests

The authors declare that they have no competing interests.

References

1. Choi WK, Cho DH, Yim CY and Lee NR: Primary hepatoid carcinoma of the ovary: A case report and review of the literature. *Medicine (Baltimore)* 99: e20051, 2020.
2. Stamatova D, Theilmann L and Spiegelberg C: A hepatoid carcinoma of the pancreatic head. *Sur Case Rep* 2: 78, 2016.

3. Soofi Y, Kanehira K, Abbas A, Aranez J, Bain A and Ylagan L: Pancreatic hepatoid carcinoma: A rare form of pancreatic neoplasm. *Diagn Cytopathol* 43: 251-256, 2015.
4. Chen TC, Huang SC, Chang HC, Yeh TS, Ng KF and Chen TC: Hepatoid microcarcinoma of the pancreas: A case report and review of the literature. *Chang Gung Med J* 35: 285-291, 2012.
5. Vanoli A, Argenti F, Vinci A, La Rosa S, Viglio A, Riboni R, Necchi V, Pugliese L, Sessa F, Pietrabissa A and Paulli M: Hepatoid carcinoma of the pancreas with lymphoid stroma: First description of the clinical, morphological, immunohistochemical, and molecular characteristics of an unusual pancreatic carcinoma. *Virchows Arch* 467: 237-245, 2015.
6. Zeng SX, Tan SW, Fong CJTH, Liang Q, Zhao BL, Liu K, Guo J and Tao J: Hepatoid carcinoma of the pancreas: A case report and review of the literature. *World J Clin Cases* 8: 1116-1128, 2020.
7. Uribe Rivera AK, Alvarez Larraondo M, Taxa Rojas L, Bravo Taxa M and Zevallos Cardenas A: Hepatoid carcinoma of the ovary-A case report and literature review. *Gynecol Oncol Rep* 32: 100564, 2020.
8. Acosta AM and Pins MR: Hepatoid carcinoma of the ovary: Clinical, histopathologic, and immunophenotypic features. *Arch Pathol Lab Med* 143: 883-889, 2019.
9. Karakas Y, Lacin S and Yalcin S: Recent advances in the management of pancreatic adenocarcinoma. *Expert Rev Anticancer Ther* 18: 51-62, 2018.
10. Tesfaye AA, Kamgar M, Azmi A and Philip PA: The evolution into personalized therapies in pancreatic ductal adenocarcinoma: Challenges and opportunities. *Expert Rev Anticancer Ther* 18: 131-148, 2018.
11. Tijeras-Raballand A, Hilmi M, Astorgues-Xerri L, Nicolle R, Bièche I and Neuzillet C: Microbiome and pancreatic ductal adenocarcinoma. *Clin Res Hepatol Gastroenterol* 45: 101589, 2021.
12. Attiye MA, Amini A, Chung V and Melstrom LG: Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King. *J Surg Oncol* 123: 1395-1404, 2021.
13. Ogden J, Xie H, Ma W and Hubbard J: The management of older adults with pancreatic adenocarcinoma. *Geriatrics* 3: 85, 2018.
14. Ushio J, Kanno A, Ikeda E, Ando K, Nagai H, Miwata T, Kawasaki Y, Tada Y, Yokoyama K, Numao N, *et al*: Pancreatic ductal adenocarcinoma: Epidemiology and risk factors. *Diagnostics (Basel)* 11: 562, 2021.
15. Panchal K, Sahoo RK, Gupta U and Chaurasiya A: Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview. *Int Immunopharmacol* 95: 107508, 2021.
16. Pang Y, Holmes MV, Chen Z and Kartsonaki C: A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma. *J Gastroenterol Hepatol* 34: 330-345, 2019.
17. Sikdar N, Saha G, Dutta A, Ghosh S, Shrikhande SV and Banerjee S: Genetic alterations of periampullary and pancreatic ductal adenocarcinoma: An overview. *Curr Genomics* 19: 444-463, 2018.
18. Garcia-Carbonero N, Li W, Cabeza-Morales M, Martinez-Useros J and Garcia-Foncillas J: New Hope for pancreatic ductal adenocarcinoma treatment targeting endoplasmic reticulum stress response: A systematic review. *Int J Mol Sci* 19: 2468, 2018.
19. Chappuis PO, Ghadirian P and Foulkes WD: The role of genetic factors in the etiology of pancreatic adenocarcinoma: An update. *Cancer Inve* 19: 65-75, 2001.
20. Duvillie B, Kourdoughli R, Druillennec S, Eychène A and Pouponnot C: Interplay between diabetes and pancreatic ductal adenocarcinoma and insulinoma: The role of aging, genetic factors, and obesity. *Front Endocrinol (Lausanne)* 11: 563267, 2020.
21. Eskelinen MJ and Haglund UH: Prognosis of human pancreatic adenocarcinoma: Review of clinical and histopathological variables and possible uses of new molecular methods. *Eur J Surg* 165: 292-306, 1999.
22. Diaz KE and Lucas AL: Familial pancreatic ductal adenocarcinoma. *Am J Pathol* 189: 36-43, 2019.
23. Bellotti R, Speth C, Adolph TE, Lass-Flörl C, Effenberger M, Öfner D and Maglione M: Micro- and mycobiota dysbiosis in pancreatic ductal adenocarcinoma development. *Cancers (Basel)* 13: 3431, 2021.
24. Bou Zerdan M, Shatila M, Sarwal D, Bouferraa Y, Bou Zerdan M, Allam S, Ramovic M and Graziano S: Single cell RNA sequencing: A new frontier in pancreatic ductal adenocarcinoma. *Cancers (Basel)* 14: 4589, 2022.
25. Kothari A and Flick MJ: Coagulation signaling through PAR1 as a therapeutic target in pancreatic ductal adenocarcinoma. *Int J Mol Sci* 22: 5138, 2021.
26. Jin T, Dai C and Xu F: Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: Recent advances and future prospects. *Ther Adv Med Oncol* 12: 175883592093303, 2020.
27. Yu X, Gu J, Fu D and Jin C: Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma? A systematic review and meta-analysis. *Int J Surg* 48: 149-154, 2017.
28. Parte S, Nimmakayala RK, Batra SK and Ponnusamy MP: Acinar to ductal cell trans-differentiation: A prelude to dysplasia and pancreatic ductal adenocarcinoma. *Biochim Biophys Acta Rev Cancer* 1877: 188669, 2022.
29. Igbini E, Guo F, Jiang SW, Kelley C and Li J: Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. *Clin Chim Acta* 488: 226-234, 2019.
30. Mere Del Aguila E, Tang XH and Gudas LJ: Pancreatic ductal adenocarcinoma: New insights into the actions of vitamin A. *Oncol Res Treat* 45: 291-298, 2022.
31. Das S and Cardin D: Targeting DNA damage repair pathways in pancreatic adenocarcinoma. *Curr Treat Options Oncol* 21: 62, 2020.
32. Schmitt A, Feldmann G, Zander T and Reinhardt HC: Targeting defects in the cellular DNA damage response for the treatment of pancreatic ductal adenocarcinoma. *Oncol Res Treat* 41: 619-625, 2018.
33. Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, Cheng H, Jin K, Ni Q, Yu X and Liu C: Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. *J Hematol Oncol* 13: 130, 2020.
34. Hayashi H, Higashi T, Miyata T, Yamashita Y and Baba H: Recent advances in precision medicine for pancreatic ductal adenocarcinoma. *Ann Gastroenterol Surg* 5: 457-466, 2021.
35. Rainone M, Singh I, Salo-Mullen EE, Stadler ZK and O'Reilly EM: An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: A review. *JAMA Oncol* 6: 764, 2020.
36. Wu C, Yang P, Liu B and Tang Y: Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma? *Onco Targets Ther* 13: 2551-2562, 2020.
37. Macchini M, Centonze F, Peretti U, Orsi G, Militello AM, Valente MM, Cascinu S and Reni M: Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients. *Cancer Treat Rev* 104: 102357, 2022.
38. Pimenta JR, Ueda SKN and Peixoto RD: Excellent response to olaparib in a patient with metastatic pancreatic adenocarcinoma with germline BRCA1 mutation after progression on FOLFIRINOX: Case report and literature review. *Case Rep Oncol* 13: 904-910, 2020.
39. Rebelatto TF, Falavigna M, Pozzari M, Spada F, Cella CA, Laffi A, Pellicori S and Fazio N: Should platinum-based chemotherapy be preferred for germline BRCA1/2 (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. *Cancer Treat Rev* 80: 101895, 2019.
40. Reinacher-Schick A, Arnold D, Venerito M, Goekkurt E, Kraeft AL and Seufferlein T: Platinum-Based chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: Summary of evidence and application in clinical practice. *Oncol Res Treat* 45: 752-763, 2022.
41. Singh RR and O'Reilly EM: New treatment strategies for metastatic pancreatic ductal adenocarcinoma. *Drugs* 80: 647-669, 2020.
42. Zemanek T, Melichar B, Lovecek M, Soucek P and Mohelnikova-Duchonova B: Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. *Pharmacogenomics* 20: 113-127, 2019.
43. Dardare J, Witz A, Merlin JL, Gilson P and Harlé A: SMAD4 and the TGF β pathway in patients with pancreatic ductal adenocarcinoma. *Int J Mol Sci* 21: 3534, 2020.
44. Jian S, Kong D and Tian J: Expression of miR-425-5p in pancreatic carcinoma and its correlation with tumor immune microenvironment. *J Invest Surg* 36: 2216756, 2023.
45. Nan P, Dong X, Bai X, Lu H, Liu F, Sun Y and Zhao X: Tumor-stroma TGF- β 1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin α v β 3/CD36-mediated activation of the MAPK pathway. *Cancer Lett* 528: 59-75, 2022.

46. Rajagopal MU, Bansal S, Kaur P, Jain SK, Altadil T, Hinzman CP, Li Y, Moulton J, Singh B, Bansal S, *et al*: TGF β drives metabolic perturbations during epithelial mesenchymal transition in pancreatic cancer: TGF β induced EMT in PDAC. *Cancers (Basel)* 13: 6204, 2021.
47. Murthy D, Attri KS and Singh PK: Phosphoinositide 3-Kinase signaling pathway in pancreatic ductal adenocarcinoma progression, pathogenesis, and therapeutics. *Front Physiol* 9: 335, 2018.
48. Dolay K, Malya FU and Akbulut S: Management of pancreatic head adenocarcinoma: From where to where? *World J Gastrointest Surg* 11: 143-154, 2019.
49. Vaish U, Jain T, Are AC and Dudeja V: Cancer-Associated fibroblasts in pancreatic ductal adenocarcinoma: An update on heterogeneity and therapeutic targeting. *Int J Mol Sci* 22: 13408, 2021.
50. Khokhar AS, Sher AF and Schattner M: Interventional endoscopy in the diagnosis and management of pancreatic adenocarcinoma. *Chin Clin Oncol* 6: 63-63, 2017.
51. Rémond MS, Pellat A, Brezault C, Dhooge M and Coriat R: Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma? *ESMO Open* 7: 100638, 2022.
52. Seo YD and Katz MHG: Preoperative therapy for pancreatic adenocarcinoma-precision beyond anatomy. *Cancer* 128: 3041-3056, 2022.
53. Lafond M, Lambin T, Drainville RA, Dupré A, Pioche M, Melodelima D and Lafon C: Pancreatic ductal adenocarcinoma: Current and emerging therapeutic uses of focused ultrasound. *Cancers (Basel)* 14: 2577, 2022.
54. Ladd AM and Diehl DL: Artificial intelligence for early detection of pancreatic adenocarcinoma: The future is promising. *World J Gastroenterol* 27: 1283-1295, 2021.
55. Constantin AL, Cazacu IM, Stroescu C, Copăescu C and Săftoiu A: Prognostic biomarkers related to tumoral microenvironment in pancreatic ductal adenocarcinoma: A systematic review. *Rom J Morphol Embryol* 62: 671-678, 2021.
56. Kulkarni NM, Mannelli L, Zins M, Bhosale PR, Arif-Tiwari H, Brook OR, Hecht EM, Kastrinos F, Wang ZJ, Soloff EV, *et al*: White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals. *Abdom Radiol (NY)* 45: 729-742, 2020.
57. Buscail E, Maulat C, Muscari F, Chiche L, Cordelier P, Dabernat S, Alix-Panabières C and Buscail L: Liquid biopsy approach for pancreatic ductal adenocarcinoma. *Cancers (Basel)* 11: 852, 2019.
58. Barhli A, Cros J, Bartholin L and Neuzillet C: Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. *Dig Liver Dis* 50: 979-990, 2018.
59. Lupinacci RM, Bachet J-B, André T, Duval A and Svrcek M: Pancreatic ductal adenocarcinoma harboring microsatellite instability/DNA mismatch repair deficiency. Towards personalized medicine. *Surg Oncol* 28: 121-127, 2019.
60. Leal AD, Messersmith WA and Lieu CH: Neoadjuvant treatment of localized pancreatic adenocarcinoma. *J Gastrointest Oncol* 12: 2461-2474, 2021.
61. Kapszewicz M and Małecka-Wojcieszko E: Simple serum pancreatic ductal adenocarcinoma (PDAC) Protein Biomarkers-Is There Anything in Sight? *J Clin Med* 10: 5463, 2021.
62. Iyengar S, Nevala-Plagemann C and Garrido-Laguna I: Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. *Ther Adv Med Oncol* 13: 175883592110458, 2021.
63. Lawlor R, Veronese N, Nottegar A, Malleo G, Smith L, Demurtas J, Cheng L, Wood LD, Silvestris N, Salvia R, *et al*: Prognostic Role of High-Grade tumor budding in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis with a focus on epithelial to mesenchymal transition. *Cancers* 11: 113, 2019.
64. O'Connor D, Brown M, Eatock M, Turkington RC and Prue G: Exercise efficacy and prescription during treatment for pancreatic ductal adenocarcinoma: A systematic review. *BMC Cancer* 21: 43, 2021.
65. Thobie A, Mulliri A, Bouvier V, Launoy G, Alves A and Dejardin O: Same chance of accessing resection? impact of socioeconomic status on resection rates among patients with pancreatic adenocarcinoma-A systematic review. *Health Equity* 5: 143-150, 2021.
66. He J, Zhao Q, Liu Q, Li F, He L, Liu M and Yan X: Surgical resection of pancreatic hepatoid carcinoma followed by combined transarterial chemoembolization and immunotherapy: A case report. *Oncotargets Ther* 14: 4575-4578, 2021.
67. Tomino T, Ninomiya M, Matono R, Narutomi F, Oshiro Y, Watanabe K, Taniguchi D, Nishimura S, Zaitzu Y, Kajiura Y, *et al*: Pure pancreatic hepatoid carcinoma: A surgical case report and literature review. *Surg Case Rep* 5: 186, 2019.
68. Zeeshan MS and Ramzan Z: Current controversies and advances in the management of pancreatic adenocarcinoma. *World J Gastrointest Oncol* 13: 472-494, 2021.
69. Gholap NN, Davies MJ, Mostafa SA and Khunti K: Diagnosing type 2 diabetes and identifying high-risk individuals using the new glycated haemoglobin (HbA1c) criteria. *Br J Gen Pract* 63: e165-e167, 2013.
70. Trinh HS, Luong TH, Lai TT and Nguyen TK: Mixed pancreatic hepatoid carcinoma: A surgical case report and literature review. *Int J Surg Case Rep* 83: 105951, 2021.
71. Cardona D, Grobmyer S, Crawford JM and Liu C: Hepatocellular carcinoma arising from ectopic liver tissue in the pancreas. *Virchows Arch* 450: 225-229, 2007.
72. Kubota K, Kita J, Rokkaku K, Iwasaki Y, Sawada T, Imura J and Fujimori T: Ectopic hepatocellular carcinoma arising from pancreas: A case report and review of the literature. *World J Gastroenterol* 13: 4270-4273, 2007.
73. Veerankutty FH, Yeldho V, Tu SA, Venugopal B, Manoj KS and Vidhya C: Hepatoid carcinoma of the pancreas combined with serous cystadenoma: A case report and review of the literature. *Hepatobiliary Surg Nutr* 4: 35462-35362, 2015.
74. Yahaya A, Wa Kammal WS, Abd Shukur N and Osman SS: Oesophageal hepatoid carcinoma with liver metastasis, a diagnostic dilemma. *Malays J Pathol* 41: 59-63, 2019.
75. Schneider S: Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection. *World J Gastroenterol* 21: 6384-6390, 2015.
76. Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M and Lauber K: Pancreatic ductal adenocarcinoma: Biological hallmarks, current status, and future perspectives of combined modality treatment approaches. *Radiat Oncol* 14: 141, 2019.
77. Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, *et al*: Metastatic pancreatic cancer: ASCO guideline update. *J Clin Oncol*: JCO2001364, 2020.
78. Brown DB, Gonsalves CF, Yeo CJ, Witkiewicz AK and Carr BI: One Year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin. *Oncol Rep* 24: 767-769, 2010.
79. Kuo PC, Chen SC, Shyr YM, Kuo YJ, Lee RC and Wang SE: Hepatoid carcinoma of the pancreas. *World J Surg Oncol* 13: 185, 2015.
80. Schawkat K, Manning MA, Glickman JN and Morteale KJ: Pancreatic ductal adenocarcinoma and its variants: Pearls and perils. *Radiographics* 40: 1219-1239, 2020.
81. Yang C, Sun L, Lai JZ, Zhou L, Liu Z, Xi Y, Tao Y, Dooley E and Cao D: Primary hepatoid carcinoma of the pancreas: A Clinicopathological study of 3 cases with review of additional 31 cases in the literature. *Int J Surg Pathol* 27: 28-42, 2019.
82. Al-Obaidy KI, Williamson SR, Shelman N, Idrees MT and Ulbright TM: Hepatoid teratoma, hepatoid yolk sac tumor, and hepatocellular carcinoma: A morphologic and immunohistochemical study of 30 cases. *Am J Surg Pathol* 45: 127-136, 2021.
83. Su JS, Chen YT, Wang RC, Wu CY, Lee SW and Lee TY: Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: A literature review. *World J Gastroenterol* 19: 321-327, 2013.
84. Lai YCC, Cheng CC, Lai YS and Liu YH: Cytokeratin 18-associated Histone 3 modulation in hepatocellular carcinoma: A mini review. *Cancer Genomics Proteomics* 14: 219-223, 2017.
85. Shimonishi T, Miyazaki K and Nakanuma Y: Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver. *Histopathology* 37: 55-63, 2000.
86. Gurzu S and Jung I: Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations. *Pathol Res Pract* 208: 163-166, 2012.
87. Yokoyama S, Hamada T, Higashi M, Matsuo K, Maemura K, Kurahara H, Horinouchi M, Hiraki T, Sugimoto T, Akahane T, *et al*: Predicted prognosis of patients with pancreatic cancer by machine learning. *Clin Cancer Res* 26: 2411-2421, 2020.

88. Al-Arashi MYH and Byers HR: Cutaneous clear cell squamous cell carcinoma in situ: Clinical, histological and immunohistochemical characterization. *J Cutan Pathol* 34: 226-233, 2007.
89. Miettinen M and Fetsch JF: Distribution of keratins in normal endothelial cells and a spectrum of vascular tumors: Implications in tumor diagnosis. *Hum Pathol* 31: 1062-1067, 2000.
90. Austgulen R, Chedwick L, Vogt Isaksen C, Vatten L and Craven C: Trophoblast apoptosis in human placenta at term as detected by expression of a cytokeratin 18 degradation product of caspase. *Arch Pathol Lab Med* 126: 1480-1486, 2002.
91. Kuan SF, Montag AG, Hart J, Krausz T and Recant W: Differential expression of mucin genes in mammary and extramammary Paget's disease. *Am J Surg Pathol* 25: 1469-1477, 2001.
92. Kirtonia A, Pandey AK, Ramachandran B, Mishra DP, Dawson DW, Sethi G, Ganesan TS, Koeffler HP and Garg M: Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade. *Cell Mol Life Sci* 79: 362, 2022.
93. Qazi AM, Gruzdyn O, Semaan A, Seward S, Chamala S, Dhulipala V, Sethi S, Ali-Fehmi R, Philip PA, Bouwman DL, *et al*: Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. *Surgery* 152: 704-713, 2012.
94. Çoban EA, Tecimil D, Kaşıkci E, Bayrak ÖF and Şahin F: E-cadherin might be a stage-dependent modulator in aggressiveness in pancreatic cancer cells. *Turk J Biol* 44: 230-237, 2020.
95. Hong SM, Li A, Olin K, Wolfgang CL, Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH and Goggins M: Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. *Mod Pathol* 24: 1237-1247, 2011.
96. Jiao F, Hu H, Han T, Zhuo M, Yuan C, Yang H, Wang L and Wang L: Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. *Oncotarget* 7: 16505-16516, 2016.
97. Zhao L, Wang YX, Xi M, Liu SL, Zhang P, Luo LL and Liu MZ: Association between E-cadherin (CDH1) polymorphisms and pancreatic cancer risk in Han Chinese population. *Int J Clin Exp Pathol* 8: 5753, 2015.
98. Saito T, Mizukami H, Umetsu S, Uchida C, Inaba W, Abe M, Takahashi K, Kudo K, Itabashi C, Yagihashi S and Hakamada K: Worsened outcome in patients with pancreatic ductal carcinoma on long-term diabetes: Association with E-cadherin1 (CDH1) promoter methylation. *Sci Rep* 7: 18056, 2017.
99. Dhayat SA, Traeger MM, Rehkaemper J, Stroese AJ, Steinestel K, Wardelmann E, Kabar I and Senninger N: Clinical impact of Epithelial-to-Mesenchymal transition regulating MicroRNAs in pancreatic ductal adenocarcinoma. *Cancers (Basel)* 10: 328, 2018.
100. Kang Y, Ling J, Suzuki R, Roife D, Chopin-Laly X, Truty MJ, Chatterjee D, Wang H, Thomas RM, Katz MH, *et al*: SMAD4 regulates cell motility through transcription of N-Cadherin in human pancreatic ductal epithelium. *PLoS One* 9: 107948, 2014.
101. Ottenhof NA, De Wilde RF, Morsink FH, de Leng WW, Ausems MG, Morreau H, van Hillegersberg R, Offerhaus GJ and Milne AN: Pancreatic ductal adenocarcinoma in hereditary diffuse gastric cancer. A case report. *Hum Pathol* 43: 457-461, 2012.
102. Zhou L, Sheng WW, Jia C, Shi X, Cao R, Wang G, Lin Y, Zhu F, Dong Q and Dong M: Musashi2 promotes the progression of pancreatic cancer through a novel ISYNA1-p21/ZEB-1 pathway. *J Cell Mol Med* 24: 10560-10572, 2020.
103. Hu D, Ansari D, Pawlowski K, Zhou Q, Sasor A, Welinder C, Kristl T, Bauden M, Rezeli M, Jiang Y, *et al*: Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma. *Oncotarget* 9: 9789-9807, 2018.
104. Kurahara H, Takao S, Maemura K, Mataka Y, Kuwahata T, Maeda K, Ding Q, Sakoda M, Iino S, Ishigami S, *et al*: Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer. *J Surg Oncol* 105: 655-661, 2012.
105. Vannier C, Mock K, Brabletz T and Driever W: Zeb1 regulates E-cadherin and Epcam (epithelial cell adhesion molecule) expression to control cell behavior in early zebrafish development. *J Biol Chem* 288: 18643-18659, 2013.
106. Yu C, Wang M, Chen M, Huang Y and Jiang J: Upregulation of microRNA-138-5p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity. *Mol Med Rep* 12: 5135-5140, 2015.
107. Lerbs T, Bisht S, Schölch S, Pecqueux M, Kristiansen G, Schneider M, Hofmann BT, Welsch T, Reissfelder C, Rahbari NN, *et al*: Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer. *BMC Cancer* 17: 249, 2017.
108. Lahat G, Lubezky N, Loewenstein S, Nizri E, Gan S, Pasmanik-Chor M, Hayman L, Barazowsky E, Ben-Haim M and Klausner JM: Epithelial-to-Mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes. *Ann Surg Oncol* 21 (Suppl 4): S750-S757, 2014.
109. Blevins MA, Towers CG, Patrick AN, Zhao R and Ford HL: The SIX1-EYA transcriptional complex as a therapeutic target in cancer. *Expert Opin Ther Targets* 19: 213-225, 2015.
110. Nomura A, Majumder K, Giri B, Dauer P, Dudeja V, Roy S, Banerjee S and Saluja AK: Inhibition of NF-kappa B pathway leads to deregulation of epithelial-mesenchymal transition and neural invasion in pancreatic cancer. *Lab Invest* 96: 1268-1278, 2016.
111. Zaheer A, Wadhwa V, Oh J and Fishman EK: Pearls and pitfalls of imaging metastatic disease from pancreatic adenocarcinoma: A systematic review. *Clin Imaging* 39: 750-758, 2015.
112. Larentzakis A, Anagnostou E, Georgiou K, Vrakopoulou GZ, Zografos CG, Zografos GC and Toutouzas KG: Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review. *Oncol Lett* 21: 246, 2021.
113. Tao L, Yuan C, Ma Z, Jiang B and Xiu D: Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: A population-based study. *Cancer Manag Res* 9: 471-479, 2017.
114. Larentzakis A, Anagnostou E, Georgiou K, Vrakopoulou GZ, Zografos C, Zografos G and Toutouzas K: Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review. *Oncol Lett* 21: 246, 2021.
115. Brind'Amour A, Webb M, Parapini M, Sid  ris L, Segedi M, Chung SW, Chartier-Plante S, Dub   P, Scudamore CH and Kim PTW: The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: A systematic review. *Clin Exp Metastasis* 38: 187-196, 2021.
116. Moletta L, Serafini S, Valmasoni M, Pierobon ES, Ponzoni A and Sperti C: Surgery for recurrent pancreatic cancer: Is it effective? *Cancers (Basel)* 11: 991, 2019.
117. La Salvia A, Persano I, Parlagreco E, Audisio A, Cani M and Brizzi MP: Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: Two sides of the moon. *Med Oncol* 39: 168, 2022.
118. Winner M, Goff SL and Chabot JA: Neoadjuvant therapy for Non-metastatic pancreatic ductal adenocarcinoma. *Semin Oncol* 42: 86-97, 2015.
119. Zhou Y, Liao S, You J and Wu H: Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: A systematic review of the published literature. *Updates Surg* 74: 43-53, 2022.
120. Liberko M, Kolostova K, Szabo A, Gurlich R, Oliverius M and Soumarova R: Circulating tumor cells, circulating tumor DNA and other blood-based prognostic scores in pancreatic ductal adenocarcinoma-mini-review. *In Vivo* 35: 31-39, 2021.
121. Attard JA, Farrugia A, Pathanki A, Roberts KJ, Dasari B, Isaac J, Ma YT and Chatzizacharias NA: Treatment strategies for the optimal management of locally advanced pancreatic adenocarcinoma with curative intent: A systematic review. *Pancreas* 49: 1264-1275, 2020.
122. Moorcraft SY, Khan K, Peckitt C, Watkins D, Rao S, Cunningham D and Chau I: FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: The royal marsden experience. *Clin Colorectal Cancer* 13: 232-238, 2014.
123. Korrel M, Lof S, Van Hilst J, Alseidi A, Boggi U, Busch OR, van Dieren S, Edwin B, Fuks D, Hackert T, *et al*: Predictors for survival in an international cohort of patients undergoing distal pancreatectomy for pancreatic ductal adenocarcinoma. *Ann Surg Oncol* 28: 1079-1087, 2021.
124. Fancellu A, Petrucciani N, Porcu A, Deiana G, Sanna V, Ninniri C, Perra T, Celoria V and Nigri G: The impact on survival and morbidity of Portal-Mesenteric resection during pancreaticoduodenectomy for pancreatic head adenocarcinoma: A systematic review and meta-analysis of comparative studies. *Cancers (Basel)* 12: 1976, 2020.

125. Chen K, Pan Y, Zhang B, Maher H and Cai X: Laparoscopic versus open pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. *Int J Surg* 53: 243-256, 2018.
126. de Liguori Carino N, O'Reilly DA, Siriwardena AK, Valle JW, Radhakrishna G, Pihlak R and McNamara MG: Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? *Eur J Surg Oncol* 44: 1486-1493, 2018.
127. Yang DJ, Xiong JJ, Lu HM, Wei Y, Zhang L, Lu S and Hu WM: The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. *Sci Rep* 9: 1159, 2019.
128. Ferreira BP, Vasquez J and Carilli A: Metastatic hepatoid carcinoma of the pancreas: First description of treatment with capecitabine and temozolomide. *Am J Med Sci* 353: 610-612, 2017.
129. Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R and Weber GF: Current clinical strategies of pancreatic cancer treatment and open molecular questions. *Int J Mol Sci* 20: 4543, 2019.
130. Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD and Del Chiaro M: Neoadjuvant treatment in pancreatic cancer. *Front Oncol* 10: 245, 2020.
131. Varghese AM, Lowery MA, Yu KH and O'Reilly EM: Current management and future directions in metastatic pancreatic adenocarcinoma: Review of metastatic pancreatic adenocarcinoma. *Cancer* 122: 3765-3775, 2016.
132. Duffy A and Kummar S: Metastatic pancreatic adenocarcinoma: Current standards, future directions. *Am J Ther* 17: 79-85, 2010.
133. Akhuba L, Tigai Z and Shek D: Where do we stand with immunotherapy for advanced pancreatic ductal adenocarcinoma: A synopsis of clinical outcomes. *Biomedicines* 10: 3196, 2022.
134. Sendur M: Current treatment options for metastatic pancreatic adenocarcinoma. *UHOD* 25: 263-274, 2015.
135. Conroy T and Mitry E: Chemotherapy of metastatic pancreatic adenocarcinoma: Challenges and encouraging results. *Bull Cancer* 98: 1439-1446, 2011 (In French).
136. Ballehaninna UK and Chamberlain RS: The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. *J Gastrointest Oncol* 3: 105-119, 2012.
137. Kriz D, Ansari D and Andersson R: Potential biomarkers for early detection of pancreatic ductal adenocarcinoma. *Clin Transl Oncol* 22: 2170-2174, 2020.
138. Wu H, Ou S, Zhang H, Huang R, Yu S, Zhao M and Tai S: Advances in biomarkers and techniques for pancreatic cancer diagnosis. *Cancer Cell Int* 22: 220, 2022.
139. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, *et al*: Serum biomarker panels for the detection of pancreatic cancer. *Clin Cancer Res* 17: 805-816, 2011.
140. Tartaglione S, Pecorella I, Zarrillo SR, Granato T, Viggiani V, Manganaro L, Marchese C, Angeloni A and Anastasi E: Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: A pilot study. *Biochem Med (Zagreb)* 29: 020707, 2019.
141. Tartaglione S, Mancini P, Viggiani V, Chirletti P, Angeloni A and Anastasi E: PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma. *PLoS One* 16: e0251656, 2021.
142. Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Eiblmaier A, Klein HG, Hegel JK, Sharma A, *et al*: Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. *JGH Open* 6: 292-300, 2022.
143. Okada KI, Kawai M, Tani M, Hirono S, Miyazawa M, Shimizu A, Kitahata Y and Yamaue H: Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma. *J Hepatobiliary Pancreat Sci* 21: 648-653, 2014.
144. Ozaki K, Hayashi H, Ikuta Y, Masuda T, Akaboshi S, Ogata K, Matumoto K, Ogawa K, Kamio T, Baba H and Takamori H: Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX. *Clin J Gastroenterol* 12: 603-608, 2019.
145. Sunagawa Y, Yamada S, Sato Y, Morimoto D, Sonohara F, Takami H, Inokawa Y, Hayashi M, Kanda M, Tanaka C, *et al*: Novel prognostic implications of DUPAN-2 in the era of initial systemic therapy for pancreatic cancer. *Ann Surg Oncol* 27: 2081-2089, 2020.
146. Takagi T, Nagai M, Nishiwada S, Terai T, Yasuda S, Matsuo Y, Doi S, Kohara Y and Sho M: Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma. *Ann Gastroenterol Surg* 7: 326-335, 2023.
147. Hosokawa Y, Nagakawa Y, Sahara Y, Takishita C, Katsumata K and Tsuchida A: Serum SPan-1 is a significant risk factor for early recurrence of pancreatic cancer after curative resection. *Dig Surg* 34: 125-132, 2017.
148. Nishio K, Kimura K, Amano R, Yamazoe S, Ohnira G, Nakata B, Hirakawa K and Ohira M: Preoperative predictors for early recurrence of resectable pancreatic cancer. *World J Surg Oncol* 15: 16, 2017.
149. Tsutsumi K, Kawamoto H, Hirao K, Sakakihara I, Yamamoto N, Noma Y, Fujii M, Kato H, Ogawa T, Ishida E, *et al*: Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. *Pancreatol* 12: 409-416, 2012.
150. Shimizu T, Asakuma M, Tomioka A, Inoue Y, Hirokawa F, Hayashi M and Uchiyama K: Span-1 and CA19-9 as predictors of early recurrence and lymph node metastasis for patients with invasive pancreatic cancer after pancreatectomy. *Am Surg* 84: 109-113, 2018.
151. Inokuchi S, Itoh S, Yoshizumi T, Yugawa K, Yoshiya S, Toshima T, Takeishi K, Iguchi T, Sanefuji K, Harada N, *et al*: Mitochondrial expression of the DNA repair enzyme OGG1 improves the prognosis of pancreatic ductal adenocarcinoma. *Pancreatol* 20: 1175-1182, 2020.
152. Miyata T, Hayashi H, Yamashita YI, Matsumura K, Nakao Y, Itoyama R, Yamao T, Tsukamoto M, Okabe H, Imai K, *et al*: Prognostic value of the preoperative tumor marker index in resected pancreatic ductal adenocarcinoma: A retrospective single-institution study. *Ann Surg Oncol* 28: 1572-1580, 2021.
153. Ishido K, Kimura N, Wakiya T, Nagase H, Hara Y, Kanda T, Fujita H and Hakamada K: Development of a biomarker-based scoring system predicting early recurrence of resectable pancreatic duct adenocarcinoma. *Ann Surg Oncol* 29: 1281-1293, 2022.
154. Kondo N, Murakami Y, Uemura K, Nakagawa N, Takahashi S, Ohge H and Sueda T: Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma. *Pancreatol* 17: 95-102, 2017.
155. Ho J, Li X, Zhang L, Liang Y, Hu W, Yau JCW, Chan H, Gin T, Chan MTV, Tse G and Wu WKK: Translational genomics in pancreatic ductal adenocarcinoma: A review with re-analysis of TCGA dataset. *Semin Cancer Biol* 55: 70-77, 2019.
156. Pietrasz D, Sereni E, Lancelotti F, Pea A, Luchini C, Innamorati G, Salvia R and Bassi C: Circulating tumour DNA: A challenging innovation to develop 'precision onco-surgery' in pancreatic adenocarcinoma. *Br J Cancer* 126: 1676-1683, 2022.
157. McGowan R, Sally A, McCabe A, Moran BM and Finn K: Circulating nucleic acids as novel biomarkers for pancreatic ductal adenocarcinoma. *Cancers (Basel)* 14: 2027, 2022.
158. Araujo RLC, Silva RO, de Pádua Souza C, Milani JM, Huguet F, Rezende AC and Gaujoux S: Does neoadjuvant therapy for pancreatic head adenocarcinoma increase postoperative morbidity? A systematic review of the literature with meta-analysis. *J Surg Oncol* 121: 881-892, 2020.
159. Tanieri P, Borghi-Scoazec G, Saurin JC, Lombard-Bohas C, Boulez J, Berger F, Hainaut P and Scoazec JY: Cytokeratin expression in adenocarcinomas of the esophagogastric junction: A comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach. *Am J Surg Pathol* 26: 1213-1221, 2002.
160. Kim MA, Lee HS, Yang H-K and Kim WH: Cytokeratin expression profile in gastric carcinomas. *Hum Pathol* 35: 576-581, 2004.
161. Xu W, Zhang MW, Huang J, Wang X, Xu SF, Li Y and Wang SJ: Correlation between CK18 gene and gastric carcinoma micro-metastasis. *World J Gastroenterol* 11: 6530-6534, 2005.
162. Chen ZM and Wang HL: Alteration of cytokeratin 7 and cytokeratin 20 expression profile is uniquely associated with tumorigenesis of primary adenocarcinoma of the small intestine. *Am J Surg Pathol* 28: 1352-1359, 2004.
163. Kelder W, van den Berg A, van der Leij J, Bleeker W, Tiebosch AT, Grond JK, Baas PC and Plukker JT: RT-PCR and immunohistochemical evaluation of sentinel lymph nodes after in vivo mapping with Patent Blue V in colon cancer patients. *Scand J Gastroenterol* 41: 1073-1078, 2006.

164. Athanassiadou P, Psyhoyiou H, Grapsa D, Gonidi M, Ketikoglou I and Patsouris E: Cytokeratin 8 and 18 expression in imprint smears of chronic viral hepatitis, autoimmune hepatitis and hepatocellular carcinoma. *Acta Cytologica* 51: 61-65, 2007.
165. Terracciano LM, Glatz K, Mhawech P, Vasei M, Lehmann FS, Vecchione R and Tornillo L: Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: An immunohistochemical and molecular study of eight cases. *Am J Surg Pathol* 27: 1302-1312, 2003.
166. Cabibi D, Licata A, Barresi E, Craxì A and Aragona F: Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract. *Pathol Res Pract* 199: 65-70, 2003.
167. Castrillon DH, Lee KR and Nucci MR: Distinction between endometrial and endocervical adenocarcinoma: An immunohistochemical study. *Int J Gynecol Pathol* 21: 4-10, 2002.
168. Chu P, Wu E and Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. *Mod Pathol* 13: 962-972, 2000.
169. Vang R, Gown AM, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD and Ronnett BM: Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: Analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. *Am J Surg Pathol* 30: 1130-1139, 2006.
170. Harnden P, Kennedy W, Andrew AC and Southgate J: Immunophenotype of transitional metaplasia of the uterine cervix. *Int J Gynecol Pathol* 18: 125-129, 1999.
171. Tot T: Patterns of distribution of cytokeratins 20 and 7 in special types of invasive breast carcinoma: a study of 123 cases. *Ann Diagn Pathol* 3: 350-356, 1999.
172. Cruz I, Ciudad J, Cruz JJ, Ramos M, Gómez-Alonso A, Adansa JC, Rodríguez C and Orfao A: Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples. *Am J Clin Pathol* 123: 66-74, 2005.
173. Leivo I: Sinonasal adenocarcinoma: Update on classification, immunophenotype and molecular features. *Head Neck Pathol* 10: 68-74, 2016.
174. Bejarano PA, Nikiforov YE, Swenson ES and Biddinger PW: Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. *Appl Immunohistochem Mol Morphol* 8: 189-194, 2000.
175. Ikeda S, Fujimori M, Shibata S, Okajima M, Ishizaki Y, Kurihara T, Miyata Y, Iseki M, Shimizu Y, Tokumoto N, *et al*: Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. *BMC Cancer* 6: 31, 2006.
176. Mhawech P, Uchida T and Pelte MF: Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. *Hum Pathol* 33: 1136-1140, 2002.



Copyright © 2023 Iliesiu et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.